Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder

NCT00004376 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

35

Enrollment

NIH

Sponsor class

Conditions

Tourette Syndrome

Interventions

DRUG: guanfacine

Sponsor

National Center for Research Resources (NCRR)

Collaborators

[object Object]